Dual HER2 blockade with pertuzumab (P) and trastuzumab (T) in patients with HER2-positive metastatic breast cancer (mBC) relapsing after adjuvant treatment with T: results from a German non-interventional study (NIS) HELENA (NCT01777958).

导出 OA

翻译打印收藏纠错

作者： Marc,Thill ^[1] ; Pauline,Wimberger ^[2] ; Andrea,Grafe ^[3] ; Peter,Klare ^[4] ; Kerstin,Luedtke-Heckenkamp ^[5] ; Dietmar,Reichert ^[6] ; Matthias,Zaiss ^[7] ; Katja,Ziegler-Löhr ^[8] ; Tanja,Eckl ^[9] ; Andreas,Schneeweiss ^[10]

作者单位： Department of Gynecology and Gynecological Oncology, Agaplesion Markus Hospital, Frankfurt A. M, Germany. marc.thill@agaplesion.de. ^[1] Department of Gynecology and Obstetrics, TU Dresden and National Center for Tumor Diseases (NCT/UCC), Dresden, Germany. ^[2] German Cancer Research Center (DKFZ), Heidelberg, Germany. ^[3] Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany. ^[4] Helmholtz-Zentrum Dresden - Rossendorf (HZDR), Dresden, Germany. ^[5] Medical Center Nordhausen gGmbH, Nordhausen, Germany. ^[6] Gynecological Out-Patient Clinic, Berlin, Germany. ^[7] Center for Oncology and Hematology, Niels-Stensen-Clinics, Franziskus-Hospital Harderberg, Georgsmarienhütte, Germany. ^[8] Center for Oncology, Westerstede, Germany. ^[9] Practice for Interdisciplinary Oncology & Hematology, Freiburg, Germany. ^[10] Practice for Gynecological Oncology, Cologne, Germany. ^[11] Roche Pharma AG, Grenzach-Wyhlen, Germany. ^[12] National Center for Tumor Diseases (NCT), Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany. ^[13]

关键词 Cancer Dual HER2 blockade HER2-positive Metastatic breast Pertuzumab Trastuzumab